Neuland Laboratories Limited shareholders approved a final dividend of ₹34 per equity share for the financial year ended March 31, 2026, during its 42nd Annual General Meeting (AGM) held on August 4, 2026. The resolution received unanimous support from voting shareholders, with 82,55,773 votes cast in favor out of 82,55,773 valid votes polled. This payout represents a dividend yield of 340% on the face value of ₹10 per share.

The meeting, conducted via Video Conferencing (VC) and Other Audio-Visual Means (OAVM) in compliance with Ministry of Corporate Affairs (MCA) and Securities and Exchange Board of India (SEBI) circulars, also addressed key governance matters. Shareholders reappointed Dr. Davuluri Rama Mohan Rao as a Director upon his retirement by rotation and appointed Dr. Mauricio Futran as a Non-Executive Non-Independent Director. The Board’s recommendation to pay commissions to Non-Executive Directors and ratify the remuneration of Cost Auditors was also approved.

Voting Results Overview

A total of 81 members attended the meeting through VC/OAVM. The voting participation rate was approximately 64.34% of the total outstanding shares. Promoter and Promoter Group holdings accounted for 99.34% of the votes polled, while Public-Institutions contributed 84.51% of their eligible votes. Public-Non Institutions had a lower participation rate of roughly 3.08%.

Governance and Procedural Details

The AGM was chaired by Dr. D.R. Rao, Executive Chairman. Ms. Sarada Bhamidipati, Company Secretary & Compliance Officer, managed the proceedings. The Statutory and Secretarial Auditor’s Reports for FY26 contained no qualifications, observations, or adverse remarks.

Shaik Razia, Partner at D. Hanumanta Raju & Co., served as the Scrutinizer for the e-voting process conducted via the National Securities Depository Limited (NSDL) platform. Remote e-voting was open from August 1, 2026, to August 3, 2026. During the meeting, shareholders who had not voted remotely were given the opportunity to cast their votes electronically, with the facility remaining open for 15 minutes after the conclusion of the meeting.

Minor dissent was observed in the resolutions concerning the appointment of Dr. Futran and the reappointment of Dr. Rao, primarily from public institutional investors. However, all resolutions were passed with the requisite majority under Regulation 44 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Neuland Laboratories has commenced commercial production of additional capacities at its Unit 1 and Unit 3 manufacturing facilities in Telangana. The operational milestone follows earlier expansion plans disclosed to investors and marks the realization of capacity additions intended to support the company’s growth trajectory. The announcement was made via a regulatory filing on July 31, 2026.

The notification was issued pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Neuland Laboratories informed both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Ltd (NSE) of the status update. The filing references previous communications dated August 1, 2024, and January 21, 2025, which outlined the progress of these expansion initiatives.

Facility Details

The commercial production has started at two specific locations within the Sangareddy District of Telangana:

Both facilities are now producing commercially at the additional capacities planned under the respective expansion projects. The commencement indicates that the infrastructure upgrades and regulatory clearances for these specific capacity additions have been successfully completed.

Strategic Implications

The ramp-up of production at Unit 1 and Unit 3 is a key operational development for Neuland Laboratories. By bringing additional capacity online, the company aims to enhance its manufacturing output capabilities. This expansion supports the firm’s ability to meet growing demand for its pharmaceutical products and active pharmaceutical ingredients (APIs). The timely execution of these projects reflects the management’s focus on scaling operations efficiently.

Sarada Bhamidipati, Company Secretary of Neuland Laboratories Limited, signed the intimation letter. The filing serves as a formal record for stakeholders and regulators regarding the company’s operational progress. No financial figures or specific volume metrics were disclosed in this particular announcement.